University of Michigan Team Returns to ALKtALK

View this recording to hear from two dedicated researchers/oncologists from the University of Michigan’s Rogel Cancer Center. Dr. Angel Qin shares information on the Gilteritinib trial that will be opening soon, while Dr. Sofia Merajver shares an update on the Judith Tam ALK Lung Cancer Research Initiative. ALK Positive, Inc Director of Research and Clinical Affairs, Dr. Ken Culver moderates. Tune in to be informed and empowered!

[@hongkongphooey-kw4nd]

Im from England,im 2/3 year alk+ diagnosed,on alectenib working great,i want to thank these brillant drs and scientists in the united states,that have created drugs that is keeping my cancer stable,and trying to cure ALK cancer....thank you.

[@elijaguy]

thanks from israel, May 2019 diagnosed, Alec since, then resistance, now since one month Lorla. lorla gives good results, it looks so, quite challenging side effects. recently bio molecular blood test, got positive at least on 9 mutations, but only some of significance.